ACTengine® IMA203 Combined With mRNA-4203 In Synovial Sarcoma AndMelanoma
Trial ID: NCT06946225
Phase: Phase 1
Status: Recruiting
Last Update Posted: January 2026
Eligibility: Adults aged 18 and older with unresectable or metastatic synovial sarcoma who are HLA-A*02:01 positive, have measurable disease and adequate organ function, and have received or declined at least one prior line of treatment.
Overview: This Phase 1 first-in-human trial evaluates IMA203 (anzutresgene autoleucel), a TCR-T cell therapy targeting PRAME, in combination with mRNA-4203, an mRNA-based therapy designed to sustain and expand the engineered T-cells. Patients first receive lymphodepleting chemotherapy, followed by a single infusion of IMA203. Starting Day 15, mRNA-4203 is given over 12 treatment cycles to keep T-cells active. The trial aims to establish a safe dose and evaluate early anti-tumor activity.
Preliminary Effectiveness: As an early Phase 1 trial, no results have been posted yet. The study will evaluate response rate, duration of response, disease control rate, and progression-free survival at one year post infusion.
Study Contact: Immatics US, Inc.
- Phone: +1 346 204-5400
- Email: ctgovinquiries@immatics.com
Treatment Centers:
United States
- University of California San Francisco, San Francisco, CA
- Dana-Farber Cancer Institute, Boston, MA
- Memorial Sloan Kettering Cancer Center, New York, NY
- MD Anderson Cancer Center, Houston, TX